Cantar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cantar

Quick Facts: Cantar (Candesartan Cilexetil)

Property Description
Active ingredient Candesartan Cilexetil (Prodrug)
Form Oral Tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of high blood pressure
Origin Synthetic, Non-peptide derivative

Cantar: Definition and Pharmacological Class

Cantar is a synthetic, prescription-only medication whose active ingredient is Candesartan Cilexetil, formulated for oral administration as a tablet. It is classified as an Angiotensin II Receptor Blocker (ARB), a therapeutic group with a clinically recognized role in managing high blood pressure and related cardiovascular conditions. The ARB classification is central to the drug's identity, signifying that it directly addresses the body's Renin-Angiotensin-Aldosterone System (RAAS) to manage vascular tension.

The active component, Candesartan Cilexetil, is a non-peptide biphenyl-tetrazole derivative. As a brand, Cantar is manufactured by Dr. Reddy's Laboratories Ltd., requiring Rx (prescription-only) status for patient access. The medication is a single-ingredient product, offering a focused intervention as an antagonist at the AT1 receptor.


Candesartan Cilexetil: Composition and General Purpose

The composition centers on Candesartan Cilexetil, which functions as a prodrug and requires conversion into its active form, candesartan, during the absorption process. This conversion method ensures the active therapeutic compound is efficiently delivered. The compound’s synthetic origin ensures a precise, controlled formulation, distinguishing it from variable natural substances.

Its general purpose is to promote healthier blood pressure levels and reduce strain on the heart. It achieves this by selectively blocking the actions of the hormone Angiotensin II, which typically causes blood vessels to constrict. This action facilitates vasodilation (vessel widening), providing an effective strategy for easing strain on the cardiovascular system by reducing circulatory resistance.

Regulatory References

  1. Candesartan - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Cantar?

Cantar: Possible Side Effects and Safety Information

Official regulatory documents classify the adverse effects of Cantar (Candesartan Cilexetil) by frequency and System-Organ Class (SOC). The most common adverse reactions reported include headache, dizziness, upper respiratory tract infection, and back pain. Reactions are officially classified as uncommon include symptomatic hypotension and hyperkalemia (elevated potassium levels), which are more frequently observed at the start of treatment or during dose escalation.


Serious Adverse Reactions and System Involvement

Cantar is associated with the risk of serious adverse reactions, although these are typically very rare. These include potentially life-threatening conditions such as Angioedema (swelling of the face, lips, or throat), which is an Immune System Disorder, and severe blood disorders like Agranulocytosis. Other serious concerns documented in the official label involve acute renal failure or significant impairment, and severe hypotension.

System-Organ Class Example Adverse Reaction (Regulatory Documented)
Vascular Disorders Hypotension (Low blood pressure)
Metabolism & Nutrition Hyperkalemia (High potassium level)
Hepatobiliary Disorders Hepatitis and elevated liver enzymes

Population-Specific Constraints

Official regulatory information includes absolute restrictions for specific populations. Cantar is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal toxicity, which includes fetal morbidity and death. It is also contraindicated in patients with severe hepatic impairment or cholestasis. Additionally, the medicine is restricted for use in infants younger than one year of age and its combination with aliskiren is prohibited in patients with diabetes or certain levels of renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Candesartan Cilexetil overdose focuses on the consequences of an exaggerated therapeutic effect. The main manifestation is anticipated to be symptomatic hypotension, which may be presented clinically as dizziness. Ingestion reports involving doses up to 672 mg have generally been associated with an uneventful recovery.


Required Emergency Actions

If symptomatic hypotension occurs, immediate symptomatic treatment must be instituted, and vital signs must be monitored. Urgent medical attention, including consulting a Regional Poison Control Center, is required when these manifestations occur. The official guidance recommends placing the patient in a supine position with the legs elevated to manage excessively low blood pressure.


Management and Procedural Notes

Management of overexposure is primarily supportive, as no specific antidote is known for Candesartan Cilexetil. If positioning is insufficient, plasma volume may need to be expanded using intravenous isotonic saline solution. A key procedural constraint documented in the prescribing information is that the active metabolite, candesartan, cannot be removed by haemodialysis.

Therapeutic Uses of Cantar

What Cantar Treats: Main Uses and Benefits

Cantar is commonly used for the long-term management of essential hypertension (high blood pressure) in adults and may be applied in specific pediatric populations, assisting with the handling of chronic systemic circulatory strain. Its application may also be considered in the treatment of symptomatic Chronic Heart Failure (CHF) and is applied in clinical settings marked by the presence of high blood pressure alongside Type 2 Diabetes Mellitus.

The core therapeutic support contributes to easing the overall symptom load related to systemic imbalance, assisting with the maintenance of functional stability over time. It may assist with providing supportive relief for symptoms related to heart failure manifestations, helping to address symptom clusters that may become intense or disruptive, such as swelling and shortness of breath. Furthermore, its application is considered relevant for easing the systemic burden in conditions involving organ-specific functional stress linked to diabetes.


Quick Fact: Relief for Circulatory Strain

Therapeutic Area Key Symptom/Condition Management
Primary Indication Sustained management of high blood pressure
Heart Support Easing the burden of chronic heart failure symptoms
Organ Protection Managing systemic strain in hypertensive patients with Type 2 Diabetes

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Cantar as stated in regulatory documents (e.g., FDA, EMA). It is based solely on documented contraindications and restrictions, without providing medical advice or therapeutic context.

Eligibility Summary

Classification Who Must Not Use Cantar Conditional Use Populations
Absolute Contraindications Patients with known hypersensitivity to Cantar or any formulation excipient. Patients with severe active hepatic impairment (e.g., Child-Pugh Class C). Use with moderate renal impairment or mild to moderate hepatic impairment is restricted, often requiring dose reduction or close monitoring.

Age and Physiological Status

  • Pediatric Patients: Use in children and adolescents (under 18 years) is typically not established or not recommended due to insufficient safety and efficacy data from clinical trials.
  • Older Adults (over 65 years): May require cautious dose selection or lower starting doses due to the potential for age-related decline in organ function.
  • Pregnancy: Not recommended during the first trimester. Use in later trimesters is justified only if the potential benefit outweighs the risk to the fetus.
  • Lactation: The drug is excreted into human milk. Regulatory labeling requires a decision to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Cantar Interactions with other medicines and products

Cantar's official interaction profile, based on government regulatory documentation, focuses on pharmacodynamic additive risks and the dual blockade of the Renin-Angiotensin System (RAS).


Interaction Classification and Restrictions

Classification Severity Interacting Medicinal Products / Categories
Contraindicated Combination Aliskiren-containing products are prohibited for co-administration in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m²).
High Risk of Dual Blockade ACE Inhibitors (e.g., Lisinopril, Enalapril), which increases the risk of hypotension, hyperkalemia, and renal function changes.
Risk of Hyperkalemia Potassium-sparing diuretics and potassium supplements, including potassium-containing salt substitutes, due to additive effects on serum potassium levels.
Impact on Renal Function/Effect Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, which may lead to a loss of antihypertensive effect and deterioration of renal function. This risk is heightened in the elderly or those with volume depletion.
Altered Concentration Lithium co-administration has been reported to cause an increase in serum lithium concentrations and subsequent toxicity.

Metabolic and Timing Status

  • Metabolic Interaction: Regulatory documents state that Cantar is not significantly metabolized by the Cytochrome P450 system, and the active component has no documented effects on these enzymes. Therefore, interactions with drugs that inhibit or are metabolized by CYP enzymes are not expected.
  • Timing Separation: There are no mandatory timing or dose separation requirements (e.g., “must be separated by X hours”) specified in the official labeling for co-administration with other medicines.

Mechanism of Action

Cantar is a monoclonal antibody designed to exert its effects by selectively targeting the bone remodeling process. It functions as an inhibitor by binding specifically to Receptor X expressed on the surface of Osteoclast Precursors and certain mature osteoclasts.

This high-affinity molecular interaction physically blocks the activation signal necessary for the differentiation and survival of these cells. By preventing the necessary signal transduction, Cantar inhibits the maturation of precursors into active, mature osteoclasts, which are the primary mediators of bone resorption.

The resulting reduction in the overall number and activity of osteoclasts leads to a system-level physiological consequence: a decrease in the rate and magnitude of bone resorption. This modulation of the bone turnover cycle shifts the balance away from bone degradation by slowing the process at the cellular level.

Dosage and Administration Information

How Cantar is Used

Cantar (Candesartan Cilexetil) is strictly for oral administration as a tablet. The medication is taken once daily, and the tablet can be administered with or without food, simplifying its incorporation into a daily routine. The typical treatment plan is for long-term management of chronic cardiovascular conditions.

Official Dosing Regimens

Dosages are defined by the specific condition being addressed, with the standard adult maintenance dose generally ranging from 8 mg to 32 mg, taken once daily. The following regimens reflect the initial usage patterns:

Indication Initial Dose Titration / Maximum Dose
Essential Hypertension (Adults) 16 mg once daily 32 mg once daily (Maximum Daily Dose)
Chronic Heart Failure (CHF) 4 mg once daily Dose generally doubled at intervals of at least two weeks up to 32 mg daily.

Administration Context and Adjustments

The dosage structure for Cantar involves a scheduled dose escalation (titration) when treating Heart Failure. This gradual increase helps the patient reach the target dose of 32 mg daily. For special populations, adjustments to the starting dose are specified. Patients with severe renal impairment or moderate hepatic impairment may be initiated on a lower dose of 4 mg once daily. For pediatric patients aged 1 to < 6 years, administration typically involves a weight-based oral suspension. If a dose is missed, the patient should proceed to take the next scheduled dose at the usual time and should not take a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Cantar

Research exploring the use of Cantar in patients with high blood pressure primarily involves numerous Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms of hypertension, with the goal of monitoring physiological strain or stress. Researchers focused on populations of adults with high blood pressure and examined outcomes such as the change in seated blood pressure measurements over defined time intervals, typically ranging from 8 to 12 weeks.

Studies reported patterns of change in blood pressure measurements in the observed populations during the short-term study periods, compared to a placebo. Despite the volume of short-term data, there is limited information on long-term cardiovascular outcomes in studies using Cantar alone, as comparative evidence for this specific endpoint versus other drug classes often relies on pooled data or observational studies.


Evidence for use in Chronic Heart Failure (CHF)

Evidence for the use of Candesartan Cilexetil in chronic heart failure was primarily gathered from large-scale, multicenter Randomized Controlled Trials which involved thousands of patients and explored outcomes related to systemic or functional imbalance over long follow-up durations.

Studies in Reduced Ejection Fraction (HFrEF)

The trials reported that the composite outcome (cardiovascular death or hospitalization) was monitored in the group studied with Cantar and compared to the placebo group. Reports described how all-cause mortality was tracked in the observed populations. However, reports noted that some patients did experience discontinuation due to changes in laboratory values, such as elevated levels of creatinine or potassium. The evidence is generally derived from settings where Cantar was used in combination with standard treatments, not as a standalone therapy.

Studies in Preserved Ejection Fraction (HFpEF)

Studies evaluated the use of Cantar in patients with symptomatic heart failure where the pumping function was preserved. The main study analysis reported that the results for the primary composite outcome were inconclusive when compared to the placebo group. Research highlights measurements for the individual event of hospitalization for heart failure, where patterns of difference were reported. The overall pattern of mortality and morbidity in patients with preserved heart function (HFpEF) did not demonstrate a significant effect on the primary combined outcome, leading to uncertainty.

Key Studies & References

  1. Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) - Overall Programme
  2. Candesartan cilexetil in heart failure assessment of reduction in mortality and morbidity (CHARM Preserved) - Clinical Study
  3. Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction (Review of RCTs on BP control)

Frequently Asked Questions (FAQ)

Common questions about Cantar (FAQ)


Q: Why do official documents say I should not use Cantar if I have a history of certain specific conditions?

Official regulatory documents define specific conditions where the medicine is not recommended (contraindicated). For example, use during the second and third trimesters of pregnancy is prohibited due to the risk of fetal toxicity (harm to the developing fetus). The contraindication for severe hepatic impairment (severe liver problems) is based on safety risk assessments, as rare post-marketing reports have included instances of acute liver injury.


Q: Are there any specific food items I should avoid while on Cantar?

The official product information states that Cantar can be administered with or without food. However, patients are explicitly advised to avoid potassium-containing salt substitutes and over-the-counter potassium supplements. Official product information only specifies avoiding these items because of the potential for additive effects that may increase the risk of hyperkalemia (high potassium levels).


Q: What evidence exists regarding the long-term safety of Cantar?

Official information and studies indicate that the blood pressure lowering effect is generally sustained during long-term treatment. Regulatory summaries note that there is limited information available from certain long-term trials that have studied Cantar as a standalone therapy for specific cardiovascular outcomes.


Q: What are the official requirements for monitoring while taking Cantar?

According to official product information, certain health factors like blood potassium levels and renal function (kidney health) often require periodic monitoring while taking Cantar. This monitoring is especially important for patients with pre-existing conditions or when taking certain interacting medications. The purpose of this monitoring is to track the medicine's effect on key physiological markers.


Q: Can Cantar affect my ability to drive or operate machinery?

Official product information contains a cautionary statement regarding potential effects on complex tasks. Since Cantar can cause side effects such as dizziness or tiredness, official product information contains a cautionary statement that these effects may temporarily impair the ability to drive or operate complex machinery.


Q: How quickly can a person expect Cantar to start working?

Official studies indicate that the onset of the blood pressure lowering effect generally occurs within two hours of taking a single dose. The full expected benefit often requires continuous use over a longer period to develop.


Q: What happens if I stop taking Cantar suddenly?

Abruptly stopping the medication may lead to uncontrolled symptoms of the condition being treated. Regulatory guidelines emphasize consulting a healthcare professional before making any change to the regimen, rather than stopping abruptly.


Q: Can Cantar be taken at the same time as my daily vitamins?

General vitamins are not typically listed in regulatory documents as an interaction risk. However, official guidelines advise caution and monitoring for any supplement that may increase potassium levels. General vitamins that do not contain potassium are not specifically mentioned as an interaction risk requiring dose separation in the official labeling.


Q: Does Cantar interact with alcohol, and what does the official warning say?

Official regulatory information does not contain a specific prohibition against consuming alcohol. However, official product information notes that because Cantar lowers blood pressure, consuming alcohol may lead to an increased likelihood of dizziness or lightheadedness.


Q: Can Cantar cause weight gain or weight loss?

Official regulatory documents, which classify adverse events by frequency, do not list weight gain or weight loss as common or serious adverse reactions associated with Cantar.


Q: Is Cantar considered a controlled substance?

Cantar (Candesartan Cilexetil) is classified as a prescription-only medicine. However, it is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or its international counterparts.


Q: Do studies suggest that the effectiveness of Cantar changes over time?

Clinical trial data states that once the maximum effect has been achieved, the effectiveness of Cantar is generally sustained during long-term treatment. Official information suggests that, once achieved, the therapeutic effect does not typically diminish over time with continued use.


Q: Is the information about Cantar the same across different countries' regulatory bodies?

International regulatory bodies, such as the European Medicines Agency (EMA), actively work to harmonize the prescribing information across regions. The goal of this process is to ensure consistent facts on indications, contraindications, and safety information.


Q: Does Cantar have a potential for dependence or addiction?

The official regulatory documents do not list physical dependence or addiction potential as an associated risk or side effect of this medicine.


Q: How long does Cantar stay in the body after the last dose?

According to official pharmacological documents, the active substance, candesartan, has an elimination half-life of approximately 9 hours. The half-life refers to the time it takes for half of the dose to be cleared from the bloodstream.


Q: Are there any documented interactions between Cantar and herbal supplements?

Official regulatory sources advise telling a healthcare provider about all prescription, over-the-counter, and herbal products being taken. This is required because the risk of potential interactions must be evaluated by a healthcare professional, even for products not explicitly listed in the main interaction warnings.


Q: If I am taking another prescription drug, how can I check for potential Cantar interactions?

The primary official guidance is to consult a healthcare provider or pharmacist before starting any new prescription medication. These professionals are best positioned to check for potential drug interactions and provide necessary guidance.


Q: What are the official warnings about taking Cantar if I have certain psychiatric conditions?

While the drug label does not list psychiatric conditions as a primary warning, post-marketing surveillance reports have rarely included adverse reactions such as depressed mood. This information is included in regulatory documents as post-marketing data for informational purposes.


Q: Does Cantar affect sleep patterns?

Pharmacological studies have reported no effect on the body's natural sleep-wake cycle (circadian rhythm). However, rare post-marketing adverse event reports have occasionally included insomnia (difficulty sleeping) or tiredness.


Q: Can Cantar be crushed or chewed, or must it be swallowed whole?

Official regulatory-linked patient information for the tablet formulation advises patients to Swallow the tablet whole. Breaking, crushing, or chewing the tablet may not be recommended. Official guidance simply instructs patients to Swallow the tablet whole.


Q: What does the manufacturer advise regarding traveling with Cantar?

Official guidelines advise storing the medicine at Controlled Room Temperature (between 20^circ textC and 25^circ textC) and protecting it from moisture and light. These guidelines for storage and protection from moisture and light are necessary to maintain the medicine's stability, including when traveling.


Q: Is Cantar known to interact with caffeine?

Official drug labels do not list a direct interaction with caffeine. However, some clinical trial protocols have specifically prohibited high dietary intake of caffeine from participants, suggesting a possible pharmacological influence that requires caution.


Q: What are the official guidelines for stopping Cantar safely?

Official guidelines do not provide a generic procedure for stopping treatment but advise that you must not stop taking the medicine without first consulting a healthcare professional. This is the primary regulatory safety guidance.


Q: Does Cantar contain any ingredients that could trigger an allergy, like dyes or gluten?

Official regulatory documents list all inactive ingredients (excipients) used in the formulation. For patients with known specific allergies, regulatory guidelines advise checking the patient information leaflet's full ingredients list or consulting a pharmacist for detailed information.


Q: What is the typical timeframe for seeing the expected results from Cantar?

Based on clinical data, most of the maximum blood pressure reduction is generally obtained within four to six weeks of starting continuous treatment. Consistency in taking the medication is key to achieving this expected result.


Q: Does Cantar interact with birth control pills?

Official regulatory documents that summarize the drug's interaction profile do not list oral contraceptives (birth control pills) as a known interaction risk.


Q: Can Cantar cause fatigue or drowsiness?

Official product information lists tiredness (fatigue) as a reported side effect, and dizziness (a common adverse reaction) is also frequently reported.


Q: Is there any information on how Cantar is eliminated from the body?

According to official pharmacological data, the drug is eliminated from the body through dual pathways, primarily via urine and in feces (following biliary excretion).

How should Cantar be stored and disposed of?

How to Store and Dispose of Cantar

Cantar (Candesartan Cilexetil) must be stored strictly according to official regulatory requirements to ensure its stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C)
Do not freeze.
Protection Keep in the original container and protect from moisture and light.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Cantar should be disposed of via an authorized drug take-back program. If a program is unavailable, disposal should follow the FDA's 'mix-and-toss' method into household trash, avoiding flushing down the toilet. The medicine is classified as an Environmentally Hazardous Substance, and special care must be taken to prevent entry into water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cantar found in:

A-Z Index: